Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States

Background: The US Food and Drug Administration has recently approved abaloparatide (ABL) for treatment of women with postmenopausal osteoporosis (PMO) at high risk of fracture. With increasing health care spending and drug prices, it is important to quantify the value of newly available treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Quang A., Hay, Joel W., Becker, Russell, Wang, Yamei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311620/
https://www.ncbi.nlm.nih.gov/pubmed/30160186
http://dx.doi.org/10.1177/1060028018798034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311620/
https://www.ncbi.nlm.nih.gov/pubmed/30160186
http://dx.doi.org/10.1177/1060028018798034

Ejemplares similares